---
document_datetime: 2025-05-05 16:47:18
document_pages: 75
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/spikevax-previously-covid-19-vaccine-moderna-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: spikevax-previously-covid-19-vaccine-moderna-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 39.9585114
conversion_datetime: 2025-12-14 21:15:27.492151
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Spikevax

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| X/0140               | Annex I_2.(c) Change or addition of a new strength/potency                                                                                   | 27/02/2025                          | 23/04/2025                                  | SmPC, Labelling and PL           |           |
| II/0147              | Submission of the final report from study mRNA- 1273-P205 listed as a category 3 study in the RMP. This is a Phase 2/3 study to evaluate the | 10/04/2025                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | immunogenicity and safety of Spikevax vaccine boosters for SARS-CoV-2 Variants. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |                                                                      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------|
| II/0148/G | This was an application for a group of variations. B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability | 03/04/2025 | n/a |                                                                      |
| II/0149   | Submission of the final report from study mRNA- 1273-P204 listed as a category 3 study in the RMP; this is interventional Phase 2/3, 3-part, dose-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 06/02/2025 | n/a | Please refer to Scientific Discussion 'Spikevax-H-C-005791- II-0149' |

<div style=\"page-break-after: always\"></div>

|         | age de-escalation and randomised, observer-blind, placebo-controlled expansion study to evaluate the safety, reactogenicity, and effectiveness of Spikevax (mRNA-1273) in children 6 months through 11 years of age. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                               |            |            |             | escalation, open-label,   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------|
| IB/0150 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 16/01/2025 | 23/04/2025 | SmPC and PL |                           |
|         | This was an application for a group of variations. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.I.b.z - Change in control of the AS - Other variation B.I.b.z - Change in control of the AS - Other variation B.I.b.z - Change in control of the AS - Other variation B.I.b.z - Change in control of the AS - Other variation B.I.b.z - Change in control of the AS - Other variation B.I.b.z - Change in control of the AS - Other | 12/12/2024 | n/a        |             | IB/0144/G                 |

<div style=\"page-break-after: always\"></div>

|           | of the AS - Other - Change in control of the AS - Other - Change in control of the AS - Other - Change in control of the AS - Other - Change in control of the AS - Other                                                                                                                                                                                                          |            |     | B.I.b.z - Change in control variation B.I.b.z variation B.I.b.z variation B.I.b.z variation B.I.b.z variation   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------|
| II/0139/G | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission competent authority                                                       | 12/12/2024 | n/a | of studies to the                                                                                               |
| IB/0145/G | This was an application for a group of variations. B.II.c.4.z - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Other variation B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.1.z - Change in the specification parameters of an excipient - Other variation | 09/12/2024 | n/a | and/or limits                                                                                                   |
| II/0123/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                 | 05/12/2024 | n/a |                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|           | Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a method   |            |     | B.I.a.1.j - biol/immunol   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------|
| II/0142   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 28/11/2024 | n/a |                            |
| II/0131   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 28/11/2024 | n/a |                            |
| IB/0143   | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 10/10/2024 | n/a |                            |
| II/0132/G | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 03/10/2024 | n/a |                            |

<div style=\"page-break-after: always\"></div>

|         | manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                         |            |            |                                  |                                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------|
| II/0136 | B.I.a.6.a - Changes to the active substance of a vaccine against human coronavirus - Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine B.I.a.6.a - Changes to the active substance of a vaccine against human coronavirus - Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine | 09/09/2024 | 10/09/2024 | SmPC, Annex II, Labelling and PL | Addition of a new strain (Spikevax JN.1, SARS-CoV-2 JN.1 mRNA) resulting in eight new monovalent presentations. |
| II/0137 | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                       | 05/09/2024 | n/a        |                                  |                                                                                                                 |
| IB/0141 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                       | 03/09/2024 | n/a        |                                  |                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| IB/0135             | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                                                                             | 09/08/2024   | n/a        |                        |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| PSUSA/10897 /202312 | Periodic Safety Update EU Single assessment - elasomeran (Spikevax), elasomeran / imelasomeran (Spikevax bivalent Original/Omicron BA.1), elasomeran / davesomeran (Spikevax bivalent Original/Omicron BA.4-5), andusomeran (Spikevax XBB.1.5)                                                                                                                                                                                          | 11/07/2024   | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0138/G         | This was an application for a group of variations. B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that affects the product information B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that affects the product information                                        | 19/06/2024   | 10/09/2024 | SmPC, Labelling and PL |                                   |
| IA/0133/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 05/06/2024   | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|           | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure   |            |            |                                  |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| IB/0127/G | This was an application for a group of variations. B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 03/06/2024 | 10/09/2024 | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0129   | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 31/05/2024   | n/a        |      |                                                                                                                                                                                                                                                             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0121/G | This was an application for a group of variations. A grouped application consisting of three Type II variations, as follows: C.I.4: Update of section 4.5 of the SmPC to add information of co-administration of Spikevax (mRNA- 1273), including its variant formulations with herpes zoster (shingles) vaccine, based on final results from Clinical Study 217670 (NCT05047770). This is a phase 3, randomised, open-label, controlled, multi- center clinical study to evaluate the immune response and safety of both herpes zoster subunit vaccine in healthy adults aged 50 years and older, and the quadrivalent seasonal influenza vaccine in healthy adults aged 18 years and older, when administered sequentially or co-administered with mRNA-1273 booster vaccination. C.I.4: Update of section 4.5 of the SmPC to add information of co-administration of Spikevax (mRNA- 1273), including its variant formulations with influenza vaccines (standard), based on final results from Clinical Study 217670 (NCT05047770). This is a phase 3, randomised, open-label, controlled, multi- center clinical study to evaluate the immune response and safety of both herpes zoster subunit vaccine in healthy adults aged 50 years and older, and the quadrivalent seasonal influenza vaccine in | 16/05/2024   | 10/09/2024 | SmPC | Spikevax (including variant formulations) can be concomitantly administered with influenza vaccines (standard and high-dose) and with herpes zoster (shingles) subunit vaccine. Different injectable vaccines should be given at different injection sites. |

<div style=\"page-break-after: always\"></div>

|           | administered sequentially or co-administered with mRNA-1273 booster vaccination. C.I.4: Update of sections 4.5 of the SmPC to add information of co-administration of Spikevax (mRNA- 1273) with influenza (high-dose) vaccines, based on final results from Clinical Study QHD00028 (NCT04969276). This is a Phase II, open-label study, to 'Assess the Safety and Immunogenicity of Fluzone High-Dose Quadrivalent (Influenza Vaccine), 2021- 2022 Formulation and a Third Dose of Moderna COVID-19 Vaccine (mRNA-1273 Vaccine) Administered Either Concomitantly or Singly in Adults 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine'. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0124/G | This was an application for a group of variations. B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 02/05/2024 | n/a |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of   |            |     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0120 | Submission of the final report from study mRNA- 1273-P301; this is a Phase 3, randomised, stratified, observer-blind, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of Spikevax in adults aged 18 years and older, listed as a category 3 study in the RMP. The RMP version 8.2 has also been approved.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 11/04/2024 | n/a |

<div style=\"page-break-after: always\"></div>

|                     | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |             |                                                                                                                                            |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10897 /202306 | Periodic Safety Update EU Single assessment - elasomeran (Spikevax), elasomeran / imelasomeran (Spikevax bivalent Original/Omicron BA.1), elasomeran / davesomeran (Spikevax bivalent Original/Omicron BA.4-5), andusomeran (Spikevax XBB.1.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 25/01/2024 | 21/03/2024 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10897/202306. |
| IB/0125             | B.I.b.z - Change in control of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 20/03/2024 | n/a        |             |                                                                                                                                            |
| II/0116/G           | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical | 07/03/2024 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| forms manufactured by complex manufacturing processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes   | B.II.b.2.c.1   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|

<div style=\"page-break-after: always\"></div>

| arrangements and quality Replacement or addition responsible for importation Not including batch control/testing B.II.b.1.a - Replacement manufacturing site for site B.II.b.2.b - Change to arrangements and quality Replacement/addition of control/testing takes place product and any of the biol/immunol method B.II.b.2.b - Change to arrangements and quality Replacement/addition of control/testing takes place product and any of the biol/immunol method B.II.b.1.c - Replacement manufacturing site for manufacturing operation(s) release/control, and secondary biol/immunol medicinal forms manufactured by processes B.II.e.1.b.2 - Change in finished product - Change container - Sterile medicinal   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IAIN/0122/G   | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                  | 30/01/2024   |            | SmPC, Annex II, Labelling and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0118/G     | This was an application for a group of variations. B.II.c.4.z - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Other variation B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation                                                                                                                                                                                                                                                                                                                                                                                                     | 15/12/2023   | n/a        |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0114/G     | This was an application for a group of variations. C.I.4 (Type II): Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC to update the safety information regarding the administration of Spikevax to individuals at least 18 years of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise, based on updated clinical literature and internal data; the Package Leaflet is updated accordingly. C.I.Z (Type IB): To update section 6.6 of the SmPC in order to clarify the handling instructions for the pre-filled syringes; the Package Leaflet is updated | 14/12/2023   | 21/03/2024 | SmPC and PL                        | The safety, reactogenicity, and immunogenicity of Spikevax (original) were evaluated in a two-part Phase 3b open-label study in adult solid organ transplant (SOT) recipients, including kidney and liver transplants (mRNA-1273-P304). A 100 microgram (0.5 mL) dose was administered, which was the dose authorised at the time of study conduct. In Part A, 128 SOT recipients received a third dose of Spikevax (original). In Part B, 159 SOT recipients received a booster dose at least 4 months after the last dose (fourth dose for mRNA vaccines and third dose for non-mRNA vaccines). Reactogenicity was consistent with the known profile of Spikevax (original). There were no unexpected safety findings. For more information, please refer to the Summary of |

<div style=\"page-break-after: always\"></div>

|           | accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                   |            |            |                                  | Product Characteristics.                                                |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------|
| II/0110   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                   | 26/10/2023 | n/a        |                                  |                                                                         |
| IB/0115   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                   | 23/10/2023 | n/a        |                                  |                                                                         |
| N/0117    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                | 20/10/2023 | 21/03/2024 | PL                               |                                                                         |
| II/0111/G | This was an application for a group of variations. B.I.a.6.a - Changes to the active substance of a vaccine against human coronavirus - Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 14/09/2023 | 15/09/2023 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'Spikevax-H-C-005791- II-0111-G'. |

<div style=\"page-break-after: always\"></div>

|           | B.I.a.6.a - Changes to the active substance of a vaccine against human coronavirus - Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                |            |     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0112/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new | 08/09/2023 | n/a |

<div style=\"page-break-after: always\"></div>

| corresponding test method B.II.b.5.b - Change to in-process applied during the manufacture product - Addition of a B.I.b.1.z - Change in the and/or limits of an AS, material/intermediate/reagent B.II.b.5.b - Change to in-process applied during the manufacture product - Addition of a B.III.2.a.2 - Change of non EU Pharmacopoeial with the Ph. Eur. or with a Member State - Excipient/AS B.II.d.2.a - Change in test product - Minor changes procedure B.II.b.5.b - Change to in-process applied during the manufacture product - Addition of a B.II.d.2.a - Change in test product - Minor changes procedure B.II.d.2.a - Change in test product - Minor changes procedure B.I.b.2.a - Change in test starting material/reagent/intermediate changes to an approved B.II.c.1.b - Change in the and/or limits of an excipient   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | corresponding test method B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                    |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0100/G | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for | 31/08/2023 | n/a |

<div style=\"page-break-after: always\"></div>

|           | biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     |       |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------|
| II/0094/G | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical | 31/08/2023 | n/a | forms |

<div style=\"page-break-after: always\"></div>

|                     | processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a   |            |            |             |                                                                                                                                            |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10897 /202212 | Periodic Safety Update EU Single assessment - elasomeran (Spikevax), elasomeran / imelasomeran (Spikevax bivalent Original/Omicron BA.1), elasomeran / davesomeran (Spikevax bivalent Original/Omicron BA.4-5), andusomeran (Spikevax XBB.1.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20/07/2023 | 29/08/2023 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10897/202212. |

<div style=\"page-break-after: always\"></div>

| IB/0107   | B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 14/08/2023   | n/a        |                        |                                                                       |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------------------------------------------|
| II/0104/G | This was an application for a group of variations. C.I.6.a: Extension of indication to include the use of Spikevax bivalent Original/Omicron BA.4-5 (50 micrograms/50 micrograms)/mL dispersion for injection in children 6 months through 4 years of age, based on data from study mRNA-1273-P306 (NCT05436834) part 1; this is an Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA-1273.214 (Original/Omicron BA.1) vaccine for SARS-CoV-2 in participants aged 6 months to < 6 years; as a consequence, sections 4.1 and 4.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7.1 of the RMP has been approved. C.I.6.a: Extension of indication to include the use of Spikevax bivalent Original/Omicron BA.4-5 (all presentations) as a single-dose in individuals 5 years of age and older, irrespective of their vaccination history, based on epidemiology and clinical data from study mRNA-1273-P306; as a consequence, section 4.2 of the SmPC is updated. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial changes throughout the SmPC, Annex II, labelling | 20/07/2023   | 11/08/2023 | SmPC, Labelling and PL | Please refer to Scientific Discussion Spikevax H-C-005791- II-0104-G. |

<div style=\"page-break-after: always\"></div>

|           | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                     |            |     |           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IB/0109/G | This was an application for a group of variations. B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                               | 03/07/2023 | n/a | procedure |
| IB/0108   | B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                              | 30/06/2023 | n/a |           |
|           | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process | 06/06/2023 | n/a | IB/0102/G |

<div style=\"page-break-after: always\"></div>

|           | - Change to in-process tests or limits during the manufacture of the finished - Tightening of in-process limits - Change to in-process tests or limits during the manufacture of the finished - Tightening of in-process limits                                                                                                                                                                                                                                                                                                          |            |     | B.II.b.5.a applied product B.II.b.5.a applied product   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------|
| IB/0105/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                    | 05/06/2023 | n/a | Other variation                                         |
| IB/0099/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.II.b.3.a - Change in the manufacturing process of | 31/05/2023 | n/a |                                                         |

<div style=\"page-break-after: always\"></div>

| the finished or intermediate in the manufacturing process B.II.b.3.z - Change in the finished or intermediate B.II.b.5.b - Change to applied during the manufacture product - Addition of a B.I.a.1.z - Change in the starting material/reagent/intermediate variation B.II.b.3.z - Change in the finished or intermediate B.II.b.5.b - Change to applied during the manufacture product - Addition of a B.I.a.2.a - Changes in the AS - Minor change of the AS B.II.e.2.z - Change in and/or limits of the immediate finished product - Other B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.b.5.z - Change to applied during the manufacture   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| II/0097/G   | This was an application for a group of variations. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or                                                                                                                                                                                                                                                                                                                                               | 26/04/2023   | 26/05/2023   | SmPC, Labelling and PL   | Please refer to Scientific Discussion 'Spikevax-H-C-005791- II-97-G'                        |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------------------------------------------------------------------------------------------|
| IB/0103/G   | This was an application for a group of variations. B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                                                                                                                                | 15/05/2023   | n/a          |                          |                                                                                             |
| II/0085/G   | This was an application for a group of variations. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 12/05/2023   | n/a          |                          |                                                                                             |
| IA/0101/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                                                                                                                                                    | 11/04/2023   | 26/05/2023   | SmPC, Annex II and PL    | The SmPC is updated to update the ATC code. Annex II is updated to remove the QC exemption. |

<div style=\"page-break-after: always\"></div>

|           | sites - Administrative change - Change in ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     | manufacturing A.6 Code/ATC   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------|
| II/0088   | Submission of the final report from study DMID 20- 0003 listed as a category 3 study in the RMP. This is a Phase I, Open Label, Dose-ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults. This submission fulfils the post-authorisation measure MEA 007.3. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission authority                                                                    | 30/03/2023 | n/a | of studies to the competent  |
| II/0093   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                  | 16/03/2023 | n/a |                              |
| IA/0096/G | This was an application for a group of variations. B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information | 01/03/2023 | n/a |                              |

<div style=\"page-break-after: always\"></div>

| starting material/reagent/intermediate variation B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.II.b.3.a - Change in the finished or intermediate in the manufacturing B.II.b.3.a - Change in the finished or intermediate in the manufacturing B.II.e.2.z - Change in and/or limits of the immediate finished product - Other B.II.b.3.a - Change in the finished or intermediate in the manufacturing B.II.b.3.a - Change in the finished or intermediate in the manufacturing B.II.b.5.b - Change to applied during the manufacture product - Addition of a B.I.a.4.a - Change to applied during the manufacture Tightening of in-process B.II.d.2.a - Change in product - Minor changes   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.e.6.b - Change in packaging material not product formulation - the product information B.III.2.b - Change to national pharmacopoeia to comply with an update of the Ph. Eur. or national Member State B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.b.5.c - Change to applied during the manufacture product - Deletion of a B.I.a.1.z - Change in the starting material/reagent/intermediate variation B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.b.3.a - Change in the finished or intermediate   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IB/0095             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 07/02/2023   | n/a        |                        |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| PSUSA/10897 /202206 | Periodic Safety Update EU Single assessment - elasomeran (Spikevax), elasomeran / imelasomeran (Spikevax bivalent Original/Omicron BA.1), elasomeran / davesomeran (Spikevax bivalent Original/Omicron BA.4-5), andusomeran (Spikevax XBB.1.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 12/01/2023   | n/a        |                        | PRAC Recommendation - maintenance |
| II/0090/G           | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical | 15/12/2022   | 16/12/2022 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | manufactured by complex manufacturing - Change to importer, batch release arrangements and quality control testing of the FP - batch control/testing for a biol/immunol and any of the test methods is a biol/immunol/immunochemical method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                        | forms processes B.II.b.2.c.3 Including product   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------|
| II/0089/G | This was an application for a group of variations. B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method B.II.b.1.c - Replacement or addition of a site for the FP - Site where any | 15/12/2022 | 16/12/2022 | SmPC, Labelling and PL | manufacturing                                    |

<div style=\"page-break-after: always\"></div>

|           | release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method   |            |            |                        |                                                                                                                                         |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| II/0083/G | This was an application for a group of variations. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                | 15/12/2022 | 16/12/2022 | SmPC, Labelling and PL | Please refer to Scientific Discussion 'Spikevax-H-C-005791- II-83-G'                                                                    |
| IB/0092   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                          | 08/12/2022 | n/a        |                        |                                                                                                                                         |
| IAIN/0091 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                  | 02/12/2022 | 02/12/2022 | SmPC and PL            | To update section 4.8 of the SmPC and section 4 of the PL to implement the signal recommendation on heavy menstrual bleeding.           |
| II/0077   | Update of section 4.8 of the SmPC to include 'Urticaria' as an adverse reaction, with the frequency 'Uncommon', as requested by the PRAC in the 13th                                                                                                                                                                                                                                                                                                                                            | 27/10/2022 | 10/11/2022 | SmPC and PL            | SmPC new text Urticaria (raised, itchy rash) has been observed with either acute onset (within a few days after vaccination) or delayed |

<div style=\"page-break-after: always\"></div>

|           | Safety Summary Report (EMEA/H/C/005791/MEA/011.12). The Package Leaflet is updated accordingly. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     | onset (up to approximately two weeks after vaccination), with the frequency 'Uncommon'. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0087/G | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a | 04/11/2022 | n/a |                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.II.b.2.b - Change to arrangements and quality Replacement/addition of control/testing takes place product and any of the biol/immunol method B.II.b.2.b - Change to arrangements and quality Replacement/addition of control/testing takes place product and any of the biol/immunol method B.II.b.2.b - Change to arrangements and quality Replacement/addition of control/testing takes place product and any of the biol/immunol method B.I.a.1.e - Change in the starting material/reagent/intermediate change relates to a biological material [-] used in the biological/immunological B.II.b.2.b - Change to arrangements and quality Replacement/addition of control/testing takes place product and any of the biol/immunol method B.II.b.1.c - Replacement manufacturing site for   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method   |            |            |                                  |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| IB/0086   | B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 25/10/2022 | n/a        |                                  |
| II/0084/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 19/10/2022 | 20/10/2022 | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|         | B.I.a.6.a - Changes to the active substance of a vaccine against human coronavirus - Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |             |                                                                      |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------|
| II/0067 | Extension of indication to include immunisation of paediatric individuals from 6 months through 5 years of age based on results from the study P204 (KidCove); this is a phase 2/3, two-part, open-label, dose-escalation, age de-escalation and randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273 SARS-CoV-2 vaccine in healthy children 6 months to less than 12 years of age. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated and the Package Leaflet is updated in accordance. The MAH also took the opportunity to implement minor editorial changes in the product information. A revised RMP version 4.1 has been approved. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 19/10/2022 | 20/10/2022 | SmPC and PL | Please refer to Scientific Discussion 'Spikevax-H-C-005791- II-0067' |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0076/G   | This was an application for a group of variations.   | 13/10/2022   | n/a   |
|-------------|------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

|           | product and is not related to a protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                                  |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| IB/0082   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 10/10/2022 | n/a        |                                  |
| II/0079/G | This was an application for a group of variations. B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 06/10/2022 | 20/10/2022 | SmPC, Annex II, Labelling and PL |
| II/0078/G | This was an application for a group of variations. B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 06/10/2022 | 20/10/2022 | SmPC, Labelling and PL           |

<div style=\"page-break-after: always\"></div>

|           | container - Sterile medicinal products and biological/immunological medicinal products B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.b.5.f - Change to in-process tests or limits applied during the manufacture of the finished product - Addition or replacement of an in-process test as a result of a safety or quality issue   |            |            |                       |                                                                                                                                                                                                                                                                                                                                                    |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0074    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 15/09/2022 | 03/10/2022 | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                                                                                                    |
| IB/0081/G | This was an application for a group of variations. B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change B.II.c.4.z - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Other variation B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation                                                               | 21/09/2022 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                    |
| II/0066   | Update of section 4.5 of the SmPC in order to indicate the possibility of co-administration of Spikevax with a high-dose quadrivalent influenza vaccine, based on the interim results from study QHD00028 (NCT04969276), a Phase II, open-label study aimed to assess the safety and                                                                                                                                                                                                                                                 | 15/09/2022 | 16/09/2022 | SmPC, Annex II and PL | Eligible participants, who received 2 doses of Spikevax at least 5 months before enrolment in the study, were randomly assigned to 1 of 3 vaccination groups: i) concomitant administration of the high-dose influenza and Spikevax vaccines, ii) administration of high-dose influenza vaccine alone, and iii) administration of Spikevax vaccine |

<div style=\"page-break-after: always\"></div>

|           | immunogenicity of a high-dose quadrivalent influenza vaccine (2021-2022 formulation) and a third dose of Spikevax administered either concomitantly or singly in adults 65 years of age and older previously primed with Spikevax. The MAH is taking the opportunity to include as editorial updates in sections 5.1 and 6.6 of the SmPC, Annex II and package leaflet, corrections from procedure EMEA/H/C/005791/II/0075. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                                  | alone. The immunogenicity responses against influenza were in general comparable between the concomitant group and the vaccine group that received high-dose influenza alone, with only a minimal, if any, trend towards higher results in the high-dose influenza alone vaccine group. This trend was not considered of clinical relevance. The immunogenicity responses against SARS-CoV-2 were also comparable with a minimal trend towards higher geometric mean titres in the Spikevax alone vaccine group as compared to the concomitant group, which was not deemed of clinical relevance. No evidence of an adverse impact on the safety profile after concomitant administration of high-dose influenza and Spikevax vaccines was observed. The study was carried out with a 100 g dose of Spikevax, instead of 50 g as approved. Nevertheless the study design per se was deemed adequate to investigate an impairment of the immune response after co-administration, independent of the dose, while creating a considerable safety margin when following   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0075/G | This was an application for a group of variations. B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.d.1.a.3 - Stability of AS - Change in the re-test                                                                               | 01/09/2022 | 01/09/2022 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| of a biological/immunological with an approved stability B.I.d.1.b.2 - Stability of conditions - Change in biological/immunological studies have not been a currently approved stability B.II.e.5.c - Change in product - Change in the sterile multidose (or single-dose, parenteral medicinal products, biological/immunological B.II.b.1.c - Replacement manufacturing site for manufacturing operation(s) release/control, and secondary biol/immunol medicinal forms manufactured by processes B.II.d.1.e - Change in and/or limits of the finished outside the approved specifications B.I.a.4.a - Change to in-process applied during the manufacture Tightening of in-process B.I.a.6.a - Changes to vaccine against human addition of a serotype, sequence or combination antigens or coding sequences coronavirus vaccine   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|        | applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the   |            |            |                                  |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| X/0065 | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 21/07/2022 | 16/08/2022 | SmPC, Annex II, Labelling and PL |
| X/0064 | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 21/07/2022 | 16/08/2022 | SmPC, Annex II, Labelling        |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                         |            |            | and PL      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10897 /202112 | Periodic Safety Update EU Single assessment - elasomeran (Spikevax), elasomeran / imelasomeran (Spikevax bivalent Original/Omicron BA.1), elasomeran / davesomeran (Spikevax bivalent Original/Omicron BA.4-5), andusomeran (Spikevax XBB.1.5)                                                                                                                          | 21/07/2022 | 16/08/2022 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10897/202112.                                                                                                                                                                                                                                                                                                                          |
| II/0057             | Update of sections 4.2 and 4.4 of the Spikevax SmPC to include a 50 g booster dose for adolescents 12 to 18 years of age, based on the extrapolation of safety and efficacy data from young adults (18 to 24 years of age). The package leaflet is updated accordingly. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 21/07/2022 | 16/08/2022 | SmPC and PL | A booster dose of Spikevax should be given intramuscularly to individuals 12 years of age and older at least 3 months after completion of the primary series. Myocarditis and pericarditis have been observed more often after the second dose compared to the first dose, and more often in younger males. The risk profile appears to be similar for the second and the third dose. For more information, please refer to the Summary of Product Characteristics. |
| IB/0072             | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                                                                                                                                 | 20/07/2022 | 16/08/2022 | SmPC        | Update of section 6.3 of the SmPC to state that stability has been demonstrated for 12 months when Spikevax is stored under certain conditions.                                                                                                                                                                                                                                                                                                                     |
| II/0073             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                          | 12/07/2022 | 16/08/2022 | Annex II    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0062             | Submission of an updated RMP version 4.0 in order to remove 'anaphylaxis' as an important identified risk; to remove 'interaction with other vaccines' as a                                                                                                                                                                                                             | 23/06/2022 | 16/08/2022 | Annex II    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           | study mRNA-1273-P904 following the outcome of the EMEA/H/C/005791/MEA/004.4 procedure; to implement the WHO-approved INN 'elasomeran'; to update the study milestones for the mRNA-1273-P301, mRNA1273-P203, mRNA-1273- P201, mRNA-1273-P901, mRNA-1273-P903 and mRNA-1273-P910 studies and to add study mRNA- 1273-P911 to the RMP. The Annex II of the Product Information is updated accordingly. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |            |          | safety concern in   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|---------------------|
| IA/0070/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                      | 15/06/2022 | 16/08/2022 | Annex II |                     |
| IB/0069   | B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 14/06/2022 | n/a        |          |                     |

<div style=\"page-break-after: always\"></div>

| IB/0071   | B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 01/06/2022   | n/a        |                            |                                                                  |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------|------------------------------------------------------------------|
| IB/0061/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test A.7 - Administrative change - Deletion of manufacturing sites B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process | 24/05/2022   | n/a        |                            |                                                                  |
| IAIN/0068 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                 | 05/05/2022   | 16/08/2022 | Annex II, Labelling and PL | To change the address of the site responsible for batch release. |
| II/0050   | B.II.b.z - Change in manufacture of the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 28/04/2022   | n/a        |                            |                                                                  |

<div style=\"page-break-after: always\"></div>

| IAIN/0063/G   | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                       | 25/04/2022   | 29/04/2022   | SmPC, Labelling and PL   | To update section 4.4 of the SmPC and section 2 of the PL to implement information on the capillary leak syndrome. The address of the MAH has also been updated.   |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0060       | B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 31/03/2022   | n/a          |                          |                                                                                                                                                                    |
| II/0059       | Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 25/03/2022   | 29/04/2022   | Annex II                 |                                                                                                                                                                    |
| II/0038/G     | This was an application for a group of variations. B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its                                                                                                                                                                                                                                              | 24/03/2022   | n/a          |                          |                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           | corresponding test method B.II.c.2.z - Change in test procedure for an excipient - Other variation B.II.c.2.z - Change in test procedure for an excipient - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                      |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0054/G | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the | 10/03/2022 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0047   | Update of section 5.1 of the SmPC in order to introduce data on the immunogenicity of Spikevax against the B.1.617.2 (Delta) variant in adults and children, based on cross-neutralisation data from studies mRNA-1273-P301 (an ongoing Phase 3, Randomized, Stratified, Observer-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older -                                                                                                                                                                                                           | 24/02/2022 | 02/03/2022 | SmPC | SmPC new text Pre-boost and post-boost neutralising antibody against the B.1.617.2 (Delta) variant in adults Results of the pseudovirus neutralisation assay (PsVNA) against the B.1.617.2 (Delta) variant determined pre- booster and on Day 29 post booster showed that administration of a booster dose of Spikevax (0.25 mL, 50 micrograms) in adults induced a 17 fold rise in neutralising |

<div style=\"page-break-after: always\"></div>

|         | NCT04470427), mRNA-1273-P201B (Part B of an ongoing Phase 2a, Randomized, Observer-Blind, Placebo-Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older - NCT04405076), and mRNA-1273-P204 (an ongoing Phase 2/3, 2- part, open-label, dose-escalation, age de-escalation and subsequent randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273 in healthy children - NCT04796896). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                        | antibodies against the Delta variant compared with pre- booster levels (GMFR = 17.28; 95% CI: 14.38, 20.77; n=295). Neutralising antibody against the B.1.617.2 (Delta) variant in children 6 through 11 years of age Serum samples of the per-protocol immunogenicity subset (n=134) of the ongoing paediatric study obtained at baseline and on Day 57 were tested in a PsVNA based on the B.1.617.2 (Delta) variant. In children 6 through 11 years of age, the GMFR from baseline to D57 was 81.77 (95% CI: 70.38, 95.00) for the Delta variant (measured by PsVNA). Furthermore, 99.3% of children met the definition of seroresponse. For more information, please refer to the Summary of   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0042 | Update of sections 4.2 and 5.1 of the SmPC in order to include information on heterologous boosting using a 50 ug dose of Spikevax to boost subjects that have previously completed a primary vaccination series with any authorised COVID-19 vaccine, and to shorten the duration of the interval between the primary series and the booster dose to 3 months, based on data from the DMID Study 21- 0012, a Phase 1/2 heterologous SARS-CoV-2 vaccine dosing (mRNA-1273 booster) study of the various vaccines authorized in the US under Emergency Use Authorisation in participants  18 years old (NCT04889209). In addition, the MAH took the                                                             | 24/02/2022 | 02/03/2022 | SmPC, Labelling and PL | SmPC new text A booster dose of Spikevax (0.25 mL, containing 50 micrograms mRNA, which is half of the primary dose) should be given intramuscularly to adults at least 3 months after completion of the primary series. Spikevax may be used to boost adults who have received a primary series with Spikevax or a primary series comprised of another mRNA vaccine or adenoviral vector vaccine. Safety and immunogenicity of a heterologous booster with Spikevax were studied in an investigator-initiated trial with 154 participants. The minimum time interval between primary series using a vector based or RNA-based COVID- 19 vaccine and booster injection with Spikevax was 12        |

<div style=\"page-break-after: always\"></div>

|         | opportunity to implement the WHO-approved INN 'elasomeran' and make minor editorial changes/corrections throughout the product information. The Annex A, the Labelling and the Package Leaflet are amended accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                       | weeks (range: 12 weeks to 20.9 weeks). The dose used for boosting in this study was 100 micrograms. Neutralising antibody titres as measured by a pseudovirus neutralisation assay were assessed on Day 1 prior to administration and at Day 15 and Day 29 after the booster dose. A booster response was demonstrated regardless of primary vaccination. Only short-term immunogenicity data are available; long-term protection and immunological memory are currently unknown. COV-BOOST is a multicentre, randomised Phase 2 investigator-initiated trial of third dose booster vaccination against COVID-19 with a subgroup to investigate detailed immunology. Participants were adults aged 30 years or older, in good physical health (mild to moderate well- controlled co-morbidities were permitted), who had received two doses of either Pfizer-BioNTech or Oxford- AstraZeneca (first dose in December 2020, January 2021 or February 2021), and were at least 84 days post second dose by the time of enrolment. Spikevax boosted antibody and neutralising responses and was well tolerated regardless of the prime series. The dose used for boosting in this study was 100 micrograms. Neutralising antibody titres as measured by a pseudovirus neutralisation assay   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0041 | Extension of indication to include use in children 6-11 years of age for Spikevax, based on data from study mRNA-1273-P204, an ongoing Phase 2/3, 2-part, open-label, dose-escalation, age de-escalation and subsequent randomized, observer-blind, placebo- controlled expansion study to evaluate the safety,                             | 24/02/2022 | 02/03/2022 | SmPC, Annex II and PL | Please refer to Scientific Discussion 'EMEA/H/C/005791/II/0041'                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | mRNA-1273 in healthy children; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. Annex II and the Package Leaflet are updated in accordance. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0052/G | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch | 24/02/2022 | n/a |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and   |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0051/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 24/02/2022 | n/a |

<div style=\"page-break-after: always\"></div>

|           | of the AS B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |             |                                                                                                                                                                                      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0055/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol | 18/02/2022 | n/a        |             |                                                                                                                                                                                      |
| IB/0056   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 15/02/2022 | 02/03/2022 | SmPC and PL | To update section 4.6 of the SmPC and section 2 of the PL to implement the recommendation on vaccination with Spikevax in pregnant women and breastfeeding as requested by the CHMP. |

<div style=\"page-break-after: always\"></div>

| IAIN/0053           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                               | 15/02/2022   | 02/03/2022   | Annex II and PL   |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10897 /202106 | Periodic Safety Update EU Single assessment - elasomeran (Spikevax), elasomeran / imelasomeran (Spikevax bivalent Original/Omicron BA.1), elasomeran / davesomeran (Spikevax bivalent Original/Omicron BA.4-5), andusomeran (Spikevax XBB.1.5)                                                                                                                                                                                                                                                                       | 27/01/2022   | 14/02/2022   | SmPC and PL       | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10897/202106. |
| II/0046             | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                                                                                                                                                                                     | 10/02/2022   | n/a          |                   |                                                                                                                                            |
| II/0028             | Submission of an updated RMP version 2.3 to include myocarditis and pericarditis as an important identified risk, as requested by PRAC as an outcome of the myocarditis and pericarditis signal assessment procedure. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 10/02/2022   | n/a          |                   |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| II/0022   | Submission of an updated RMP version 2.3 to include clinical safety data from study mRNA-1273 P203 (NCT04649151), a Phase 2/3, randomised, observer- blind, placebo-controlled study evaluating the safety, reactogenicity, and effectiveness of the mRNA-1273 vaccine in healthy adolescents aged  12 to < 18 years. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   | 10/02/2022   | n/a   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IB/0049   | B.II.b.5.f - Change to in-process tests or limits applied during the manufacture of the finished product - Addition or replacement of an in-process test as a result of a safety or quality issue                                                                                                                                                                                                                                                                                                                                                                                                                       | 28/01/2022   | n/a   |
| IB/0048/G | This was an application for a group of variations. B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation                                                                                                                                                                                                                                                                                                                                                                                    | 22/12/2021   | n/a   |
| II/0043/G | This was an application for a group of variations. B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 16/12/2021   | n/a   |

<div style=\"page-break-after: always\"></div>

|           | requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study B.II.z - Quality change - Finished product - Other variation B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products                                   |            |            |             |                                                                                                                                                                                              |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0044/G | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product B.II.f.1.e - Stability of FP - Change to an approved | 08/12/2021 | 08/12/2021 | SmPC and PL | To update the shelf life from 7 to 9 months and to update the storage claim to remove the statement to not store on dry ice.                                                                 |
| IAIN/0045 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                       | 07/12/2021 | 08/12/2021 | SmPC and PL | To update sections 4.4 and 4.8 of the SmPC and sections 2 and 4 of the PL to implement the signal recommendations on 'Signal assessment report on myocarditis and pericarditis with Spikevax |
| II/0024/G | This was an application for a group of variations. B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of                                                                                                                                                                                                                                 | 25/11/2021 | n/a        |             |                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| specification limits for OCABR B.I.b.1.e - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter effect on the overall quality B.II.d.1.e - Change in and/or limits of the finished outside the approved specifications B.II.d.1.e - Change in and/or limits of the finished outside the approved specifications B.II.d.1.b - Change in and/or limits of the finished specification limits for OCABR B.II.d.1.b - Change in and/or limits of the finished specification limits for OCABR B.II.d.1.b - Change in and/or limits of the finished specification limits for OCABR B.II.d.1.b - Change in and/or limits of the finished specification limits for OCABR B.II.d.1.b - Change in and/or limits of the finished   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR   |            |            |             |                                                                                                                                       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------|
| IB/0039/G | This was an application for a group of variations. B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.4.z - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Other variation                                                                             | 23/11/2021 | n/a        |             |                                                                                                                                       |
| IAIN/0040 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                               | 11/11/2021 | 11/11/2021 | SmPC and PL | To update section 4.8 of the SmPC and section 4 of the PL to implement the signal recommendation on erythema multiforme.              |
| II/0015/G | This was an application for a group of variations. Grouped variation to address PRAC requests raised in                                                                                                                                                                                                                                                                                                                                                                                                                      | 28/10/2021 | 03/11/2021 | SmPC and PL | SmPC new text The median time to onset of injection site reactions was 9 days after the first injection, and 11 days after the second |

<div style=\"page-break-after: always\"></div>

|         | the 3rd Spikevax Monthly Safety Summary Report (MSSR) procedure (EMEA/H/C/005791/MEA/011.2): - Update of section 4.8 of the SmPC to include details regarding time to onset and duration of the delayed injection site reactions. The Package Leaflet is updated accordingly. - Update of section 4.8 of the SmPC to include 'diarrhoea' as an adverse reaction, with the frequency 'Common'. The Package Leaflet is updated accordingly. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to make minor editorial changes. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with   |            |            |                        | injection. Median duration was 4 days after the first injection, and 4 days after the second injection. For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0034 | To update sections 2, 4.2, 4.4, 4.8, 5.1, 6.5 and 6.6 of the SmPC to include a booster dose for Spikevax, based on new clinical data from studies mRNA-1273- P201, a Phase 2a, Randomized, Observer-Blind, Placebo-Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older (NCT04405076), mRNA-1273-P301, an ongoing Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged                                                                                                                                           | 25/10/2021 | 29/10/2021 | SmPC, Labelling and PL | SmPC new text A booster dose (0.25 mL, containing 50 micrograms mRNA, which is half of the primary dose) of Spikevax may be administered intramuscularly at least 6 months after the second dose in individuals 18 years of age and older. The decision when and for whom to implement a third dose of Spikevax should be made based on available vaccine effectiveness data, taking into account limited safety data. The risk of myocarditis after a third dose (0.5 mL, 100 micrograms) or booster dose (0.25 mL, 50 micrograms) of Spikevax has not yet been characterised. The safety, reactogenicity, and immunogenicity of a |

<div style=\"page-break-after: always\"></div>

|           | 18 Years and Older (NCT04470427) and DMID 21- 0012, a Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (NCT04889209). The labelling and the package leaflet are updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                     |            |     | booster dose of Spikevax are evaluated in an ongoing Phase 2, randomised, observer-blind, placebo-controlled, dose-confirmation study in participants 18 years of age and older (NCT04405076). In this study, 198 participants received two doses (0.5 mL, 100 micrograms 1 month apart) of the Spikevax vaccine primary series. In an open- label phase of this study, participants received a single booster dose (0.25 mL, 50 micrograms) at least 6 months after receiving the second dose of the primary series. The solicited adverse reaction profile for the booster dose was similar to that after the second dose in the primary series. A single booster dose was shown to result in a geometric mean fold rise (GMFR) of 12.99 (95% CI: 11.04, 15.29) in neutralising antibodies from pre-booster compared to 28 days after the booster dose. The GMFR in neutralising antibodies was 1.53 (95% CI: 1.32, 1.77) when compared 28 days post dose 2 (primary series) to 28 days after the booster dose. For more information, please refer to the Summary of   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0037/G | This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.4.z - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Other variation B.II.c.4.z - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Other variation B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation | 13/10/2021 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|         | and/or limits of an excipient - Other variation B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change                                                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0036 | B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                   | 06/10/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0035 | B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study                                                                                                                                                                                                                                                                                                       | 05/10/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0031 | Update of sections 4.2 and 4.4 of the SmPC in order to introduce a third dose of Spikevax in the primary vaccination schedule for individuals 12 years of age and older who are severely immunocompromised, based on published literature data; the Package Leaflet is updated accordingly. The MAH took the opportunity to make minor administrative and editorial corrections throughout the product information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 04/10/2021 | 05/10/2021 | SmPC and PL | SmPC new text A third dose may be given at least 28 days after the second dose to individuals who are severely immunocompromised. The recommendation to consider a third dose (0.5 mL) is based on limited serological evidence with patients who are immunocompromised after solid organ transplantation. For more information, please refer to the Summary of Product Characteristics. Please refer to Scientific Discussion 'Spikevax/H/C/005791/II/31' |
| R/0025  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 16/09/2021 | 04/10/2021 | Annex II    | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |          | having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional marketing authorisation for Spikevax, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. Please refer to Scientific Discussion 'Spikevax/H/C/005791/R/25'   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0033/G | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other | 17/09/2021 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0030/G | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                         | 30/08/2021 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0029/G | This was an application for a group of variations. B.II.c.z - Change in control of excipients in the                                                                                                                                                                                                                                                                                                                                                                                  | 23/08/2021 | 04/10/2021 | Annex II | The Annex IIA has been updated as follows: The time-limited exemption allowing reliance on batch control testing conducted in the registered site(s) that are                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Finished Product - Other variation B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical   | located in a third country is extended from 31 July 2021 to 31 July 2022.   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | - Change to importer, batch release and quality control testing of the FP - Replacement/addition of a site where batch takes place for a biol/immunol and any of the test methods at the site is a method                                                                                                                                                                                                                                                                                 |            |     | processes B.II.b.2.b arrangements control/testing product biol/immunol   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------|
| IB/0020/G | application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing including the RMP - Other variation                         | 03/08/2021 | n/a | This was an authorisation,                                               |
| II/0026/G | This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS | 30/07/2021 | n/a |                                                                          |

<div style=\"page-break-after: always\"></div>

| II/0021   | Extension of indication to include use in adolescents from 12 to 17 years of age for Spikevax; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC and Annex II.E are updated. The Package Leaflet is updated in accordance. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   | 23/07/2021   | 23/07/2021   | SmPC, Annex II and PL            | Please refer to Scientific Discussion 'EMEA/H/C/005791/II/0021`                                                                                                                                                                                                   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0027 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                         | 12/07/2021   | 13/07/2021   | SmPC and PL                      | To update sections 4.4 and 4.8 of the SmPC and sections 2 and 4 of the PL to implement the signal recommendations from the PRAC Signal assessment report on myocarditis and pericarditis with Spikevax (EPITT no 19713) adopted at the 08 July 2021 PRAC meeting. |
| IA/0019   | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                                                                                                                                                                                                                                        | 22/06/2021   | 13/07/2021   | SmPC, Annex II, Labelling and PL | To update the invented name of the vaccine from COVID- 19 Vaccine Moderna to Spikevax.                                                                                                                                                                            |
| IB/0017   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                          | 22/06/2021   | 13/07/2021   | Annex II                         | Update of Annex II of the product information to extend the due date for SOB3.                                                                                                                                                                                    |
| IB/0023/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.II.c.2.z - Change in test procedure for an excipient - Other variation                                                                                                        | 18/06/2021   | n/a          |                                  |                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0018/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 11/06/2021   | 13/07/2021   | Annex II   | The SmPC section 6.1 and Annex II.A has been updated as                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method |              |              |            | follows: 6.1. List of excipients Lipid SM-102 (heptadecan-9-yl 8-{(2-hydroxyethyl)[6-oxo- 6-(undecyloxy)hexyl]amino}octanoate) Annex II.A. Name and address of the manufacturer responsible for batch release Recipharm Monts 18 Rue de Montbazon Monts, France 37260 In view of the declared Public Health Emergency of International Concern and in order to ensure early supply this medicinal product is subject to a time-limited exemption allowing reliance on batch control testing conducted in the registered site(s) that are located in a third country. This exemption ceases to be valid on 31 July 2021. Implementation of EU based batch control arrangements, including the necessary variations to the terms of the marketing authorisation, has to be completed by 31 July 2021 at the latest, in line with the agreed plan for this transfer of testing. The PL have been updated accordingly. |

<div style=\"page-break-after: always\"></div>

| biological/immunological B.II.b.2.b - Change to arrangements and quality Replacement/addition of control/testing takes place product and any of the biol/immunol method B.II.b.2.b - Change to arrangements and quality Replacement/addition of control/testing takes place product and any of the biol/immunol method B.II.a.3.b.3 - Changes (excipients) of the finished - Change that relates to product B.II.b.2.c.3 - Change to arrangements and quality Including batch control/testing product and any of the biol/immunol/immunochemical B.II.e.1.b.2 - Change in finished product - Change container - Sterile medicinal biological/immunological B.II.b.1.c - Replacement manufacturing site for manufacturing operation(s) release/control, and secondary biol/immunol medicinal   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | processes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |          |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|
| II/0016/G | This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is | 04/06/2021 | 13/07/2021 | Annex II |

<div style=\"page-break-after: always\"></div>

| change requires an assessment of comparability B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| biol/immunol medicinal forms manufactured by processes B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.II.c.1.a - Change in the and/or limits of an excipient specification limits B.II.b.2.a - Change to importer, arrangements and quality Replacement/addition of control/testing takes place B.I.a.1.e - Change in the starting material/reagent/intermediate change relates to a biological material [-] used in the biological/immunological B.II.b.2.a - Change to importer, arrangements and quality Replacement/addition of control/testing takes place B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.j - Change in the starting material/reagent/intermediate   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | takes place and any of the test method at the site is a biol/immunol method A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                               |            |            |             | control/testing   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------|
| II/0013/G | This was an application for a group of variations. B.II.f.1.b.2 - Stability of FP - Extension of the shelf life of the finished product - After first opening (supported by real time data) B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol Stability of FP - Other variation           | 25/05/2021 | 13/07/2021 | SmPC and PL | B.II.f.z -        |
| IB/0014/G | This was an application for a group of variations. B.II.c.4.z - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Other variation B.II.c.4.z - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation A.7 - Administrative change - Deletion of manufacturing sites | 20/05/2021 | n/a        |             |                   |

<div style=\"page-break-after: always\"></div>

| IB/0012   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                   | 12/05/2021   | 13/07/2021   | Annex II   | Annex II of the product information is updated to extend the due date for SO2.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------|----------------------------------------------------------------------------------|
| IB/0005   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                   | 11/05/2021   | n/a          |            |                                                                                  |
| IB/0010/G | This was an application for a group of variations. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                   | 03/05/2021   | n/a          |            |                                                                                  |
| IB/0009/G | This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation | 03/05/2021   | n/a          |            |                                                                                  |
| N/0006    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                | 29/04/2021   | 13/07/2021   | PL         |                                                                                  |
| II/0011/G | This was an application for a group of variations. B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new                                                                                                                                                                                      | 22/04/2021   | n/a          |            |                                                                                  |

<div style=\"page-break-after: always\"></div>

|           | container - Sterile medicinal products and biological/immunological medicinal products B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |          |                                                                               |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-------------------------------------------------------------------------------|
| IB/0008   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 20/04/2021 | n/a        |          |                                                                               |
| IB/0002   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 12/04/2021 | 13/07/2021 | Annex II | Annex II of the product information is updated to extend the due date of SOB1 |
| II/0004/G | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test | 09/04/2021 | n/a        |          |                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |          |                                                                                                                                                                                                                                      |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0007/G | This was an application for a group of variations. B.II.b.1.d - Replacement or addition of a manufacturing site for the FP - Site which requires an initial or product specific inspection B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change | 18/03/2021 | 13/07/2021 | Annex II | The SmPC Annex II.A has been updated as follows: Name and address of the manufacturer of the biological active substance LONZA AG Lonzastrasse 2 Visp 3930 Switzerland LONZA AG Ibex Solutions Rottenstrasse 6 Visp 3930 Switzerland |

<div style=\"page-break-after: always\"></div>

|         | biological/immunological medicinal product or a new bioequivalence study B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs   |            |     |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0003 | B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                 | 23/02/2021 | n/a |
| II/0001 | B.II.a.3.b.3 - Changes in the composition (excipients) of the finished product - Other excipients - Change that relates to a biological/immunological product                                                                        | 15/02/2021 | n/a |